The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis

Immunotherapy

Volumn 4, Issue 5, 2012, Pages 529-547

  Auletta, Jeffery J ^a   Bartholomew, Amelia M ^b   Maziarz, Richard T ^c   Deans, Robert J ^a,d   Miller, Robert H ^a   Lazarus, Hillard M ^a   Cohen, Jeffrey A ^a,e  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d ATHERSYS INC   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

experimental autoimmune encephalomyelitis; IFN ; immunomodulation; inflammation; mesenchymal stromal cell; multiple sclerosis; Th17 cell; Toll like receptor; transplantation

Indexed keywords

CYCLOOXYGENASE 2; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MYELOID DIFFERENTIATION FACTOR 88; NITRIC OXIDE; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ASTROCYTE; AUTOIMMUNITY; AXONAL INJURY; CELL DAMAGE; CELL THERAPY; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CHILDHOOD LEUKEMIA; CYTOKINE PRODUCTION; DEMYELINATION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOREGULATION; INFECTION; INNATE IMMUNITY; MESENCHYMAL STEM CELL TRANSPLANTATION; MICROGLIA; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OLIGODENDROGLIA; OSTEOSARCOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; TH1 CELL; TH17 CELL; TISSUE INJURY; TREATMENT OUTCOME;

ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; IMMUNOMODULATION; MESENCHYMAL STROMAL CELLS; MULTIPLE SCLEROSIS; REGENERATION; TISSUE THERAPY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84861677241     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.41     Document Type: Review

References (171)

1. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - The plaque and its pathogenesis. N. Engl. J. Med. 354(9), 942-955 (2006).
2. Mix E, Meyer-Rienecker H, Hartung HP, Zettl UK. Animal models of multiple sclerosis - Potentials and limitations. Prog. Neurobiol. 92(3), 386-404 (2010).
3. Carrithers MD. Current immunotherapy of multiple sclerosis and future challenges: Relevance of immune-mediated repair. Curr. Pharm. Biotechnol. (2012) (Epub ahead of print).
4. The Lenercept Multiple Sclerosis Study Group; the University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS. Results of a randomized, placebo-controlled multicenter study. Neurology 53, 457-465 (1999).
5. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 284(5411), 143-147 (1999).
6. Rosada C, Justesen J, Melsvik D, Ebbesen P, Kassem M. The human umbilical cord blood: A potential source for osteoblast progenitor cells. Calcif. Tissue Int. 72(2), 135-142 (2003).
7. Igura K, Zhang X, Takahashi K, Mitsuru A, Yamaguchi S, Takashi TA. Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta. Cytotherapy 6(6), 543-553 (2004).
8. Siepe M, Thomsen AR, Duerkopp N et al. Human neonatal thymus-derived mesenchymal stromal cells: Characterization, differentiation, and immunomodulatory properties. Tissue Eng. Part A 15(7), 1787-1796 (2009).
9. Zhang Q, Shi S, Liu Y, Uyanne J, Shi Y, Le AD. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J. Immunol. 183(12), 7787-7798 (2009).
10. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4), 315-317 (2006).
11. Auletta JJ, Cooke KR, Solchaga LA, Deans RJ, van't Hof W. Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: Current impact and future directions. Biol. Blood Marrow Transplant. 16(7), 891-906 (2010).
12. Siatskas C, Payne NL, Short MA, Bernard CC A consensus statement addressing mesenchymal stem cell transplantation for multiple sclerosis: It's time! Stem Cell Rev. 6(4), 500-506 (2010).
13. Freedman MS, Bar-Or A, Atkins HL et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: Consensus report of the International MSCT Study Group. Mult. Scler. 16(4), 503-510 (2010).
14. Maltman DJ, Hardy SA, Przyborski SA. Role of mesenchymal stem cells in neurogenesis and nervous system repair. Neurochem. Int. 59(3), 347-356 (2011).
15. Opitz CA, Litzenburger UM, Lutz C et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase 1 via interferon-beta and protein kinase R. Stem Cells 27(4), 909-919 (2009).
16. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin. Exp. Immunol. 149(2), 353-363 (2007).
17. Gambuzza M, Licata N, Palella E et al. Targeting Toll-like receptors: Emerging therapeutics for multiple sclerosis management. J. Neuroimmunol. 239(1-2), 1-12 (2011).
18. Codarri L, Fontana A, Becher B. Cytokine networks in multiple sclerosis: lost in translation. Curr. Opin Neurol. 23(3), 205-211 (2010).
19. Krishnamoorthy G, Wekerle H. EAE: An immunologist's magic eye. Eur. J. Immunol. 39(8), 2031-2035 (2009).
20. Marta M. Toll-like receptors in multiple sclerosis mouse experimental models. Ann. NY Acad. Sci. 1173, 458-462 (2009).
21. Steinman L. Multiple sclerosis: A two-stage disease. Nat. Immunol. 2(9), 762-764 (2001).
22. Guo X, Harada C, Namekata K et al. Regulation of the severity of neuroinflammation and demyelination by TLR-ASK1-p38 pathway. EMBO Mol. Med. 2(12), 504-515 (2010).
23. Franklin RJ. Why does remyelination fail in multiple sclerosis? Nat. Rev. Neurosci. 3(9), 705-714 (2002).
24. Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: A new strategy for immunosuppression? Trends Immunol. 28(5), 219-226 (2007).
25. Bai L, Lennon DP, Eaton V et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 57(11), 1192-1203 (2009).
26. Zhang J, Li Y, Chen J. Human bone marrow stromal cell treatment improves neruological functional recovery in EAE mice. Exp. Neurology 195, 16-26 (2005).
27. Gerdoni E, Gallo B, Casazza S et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann. Neurol. 61(3), 219-227 (2007).
28. Zappia E, Casazza S, Pedemonte E. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T cell anergy. Blood 106(5), 1755-1761 (2005).
29. Miller RH, Bai L. Cellular approaches for stimulating CNS remyelination. Regen. Med. 2(5), 817-829 (2007).
30. Romieu-Mourez R, Coutu DL, Galipeau J. The immune plasticity of mesenchymal stromal cells from mice and men: Concordances and discrepancies. Front. Biosci. (Elite Ed.) 4, 824-837 (2012).
31. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 110(10), 3499-3506 (2007).
32. Zepp J, Wu L, Li X. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol. 32(5), 232-239 (2011).
33. Gage FH. Mammalian neural stem cells. Science 287, 1433-1438 (2000).
34. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255, 1707-1710 (1992).
35. Fuller ML, DeChant AK, Rothstein B et al. Bone morphogenetic proteins promote gliosis in demyelinating spinal cord lesions. Ann. Neurol. 62(3), 288-300 (2007).
36. Munoz JR, Stoutenger BR, Robinson AP, Spees JL, Prockop DJ. Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. Proc. Natl Acad. Sci. USA 102(50), 18171-18176 (2005).
37. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76(8), 1208-1213 (2003).
38. Oswald J, Boxberger S, Jorgensen B et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 22(3), 377-384 (2004).
39. Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418(6893), 41-49 (2002).
40. Rutenberg MS, Hamazaki T, Singh AM, Terada N. Stem cell plasticity, beyond alchemy. Int. J. Hematol. 79(1), 15-21 (2004).
41. Rivera FJ, Couillard-Despres S, Pedre X et al. Mesenchymal stem cells instruct oligodendrogenic fate decision on adult neural stem cells. Stem Cells 24(10), 2209-2219 (2006).
42. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11(5), 373-384 (2010).
43. An H, Xu H, Yu Y et al. Up-regulation of TLR9 gene expression by LPS in mouse macrophages via activation of NF kappaB, ERK and p38 MAPK signal pathways. Immunol. Lett. 81(3), 165-169 (2002).
44. De Rycke L, Vandooren B, Kruithof E, De Keyser F, Veys EM, Baeten D. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis Rheum. 52(7), 2146-2158 (2005).
45. Sallusto F, Palermo B, Lenig D et al. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur. J. Immunol. 29(5), 1617-1625 (1999).
46. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34(5), 637-650 (2011).
47. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 28, 367-388 (2010).
48. Andersson A, Covacu R, Sunnemark D et al. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J. Leukoc. Biol. 84(5), 1248-1255 (2008).
49. Mills KH. TLR dependent T cell activation in autoimmunity. Nat. Rev. Immunol. 11(12), 807-822 (2011).
50. Gutcher I, Donkor MK, Ma Q, Rudensky AY, Flavell RA, Li MO. Autocrine transforming growth factor-beta1 promotes in vivo Th17 cell differentiation. Immunity 34(3), 396-408 (2011).
51. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy. J. Neurol. 251(3), 261-268 (2004).
52. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 347(12), 911-920 (2002).
53. Krone B, Grange JM. Multiple sclerosis: Are protective immune mechanisms compromised by a complex infectious background? Autoimmune Dis. 2011, 708750 (2010).
54. Carty M, Bowie AG. Evaluating the role of Toll-like receptors in diseases of the central nervous system. Biochem. Pharmacol. 81(7), 825-837 (2011).
55. Touil T, Fitzgerald D, Zhang GX, Rostami A, Gran B. Cutting edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN beta. J. Immunol. 177(11), 7505-7509 (2006).
56. Darlington PJ, Boivin MN, Renoux C et al. Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. Ann. Neurol. 68(4), 540-545 (2010).
57. Griffin MD, Ritter T, Mahon BP. Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum. Gene Ther. 21(12), 1641-1655 (2010).
58. Singer NG, Caplan AI. Mesenchymal stem cells: Mechanisms of inflammation. Annu. Rev. Pathol. 6, 457-478 (2011).
59. Bassi EJ, De Almeida DC, Moraes-Vieira PM, Camara NO. Exploring the role of soluble factors associated with immune regulatory properties of mesenchymal stem cells. Stem Cell Rev. doi:10.1007/s12015-011-9311-1 (2011) (Epub ahead of print).
60. Ghannam S, Pene J, Torcy-Moquet G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J. Immunol. 185(1), 302-312 (2010).
61. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(high) forkhead box P3+ regulatory T cells. Clin. Exp. Immunol. 156(1), 149-160 (2009).
62. Chiesa S, Morbelli S, Morando S et al. Mesenchymal stem cells impair in vivo T cell priming by dendritic cells. Proc. Natl Acad. Sci. USA 108(42), 17384-17389 (2011).
63. Krampera M. Mesenchymal stromal cell 'licensing': A multistep process. Leukemia 25(9), 1408-1414 (2011).
64. Bunnell BA, Betancourt AM, Sullivan DE. New concepts on the immune modulation mediated by mesenchymal stem cells. Stem Cell Res. Ther. 1(5), 34 (2010).
65. DelaRosa O, Lombardo E. Modulation of adult mesenchymal stem cells activity by Toll-like receptors: Implications on therapeutic potential. Mediators Inflamm. 2010, 865601 (2010).
66. Auletta JJ, Deans RJ, Bartholomew AM. Emerging roles for multipotent, bone marrow-derived stromal cells in host defense. Blood 119(8), 1801-1809 (2012).
67. Dazzi F, Krampera M. Mesenchymal stem cells and autoimmune diseases. Best Pract. Res. Clin. Haematol. 24(1), 49-57 (2011).
68. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: Polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS ONE 5(4), e10088 (2010).
69. Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES, Scandurro AB. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 26(1), 99-107 (2008).
70. Jack CS, Arbour N, Manusow J et al. TLR signaling tailors innate immune responses in human microglia and astrocytes. J. Immunol. 175(7), 4320-4330 (2005).
71. Bsibsi M, Persoon-Deen C, Verwer RW, Meeuwsen S, Ravid R, Van Noort JM. Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators. Glia 53(7), 688-695 (2006).
72. Prehaud C, Megret F, Lafage M, Lafon M. Virus infection switches TLR 3-positive human neurons to become strong producers of beta interferon. J. Virol. 79(20), 12893-12904 (2005).
73. Liu Y, Wang L, Kikuiri T et al. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-gamma and TNF-Alpha. Nat. Med. 17(12), 1594-1601 (2011).
74. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J. Cell. Biochem. 98(5), 1076-1084 (2006).
75. Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 101(8), 2999-3001 (2003).
76. English K, Barry FP, Field-Corbett CP, Mahon BP. IFN-gamma and TNF-Alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol. Lett. 110(2), 91-100 (2007).
77. Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: A novel type of alternatively activated macrophages. Exp. Hematol. 37(12), 1445-1453 (2009).
78. Chen L, Tredget EE, Wu PY, Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE 3(4), e1886 (2008).
79. Nakajima H, Uchida K, Rodriguez Guerrero A et al. Transplantation of mesenchymal stem cells promotes the alternative pathway of macrophage activation and functional recovery after spinal cord injury. J. Neurotrauma doi:10.1089/neu.2011.2109 (2012) (Epub ahead of print).
80. Chan JL, Tang KC, Patel AP et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 107(12), 4817-4824 (2006).
81. Stagg J. Immune regulation by mesenchymal stem cells: Two sides to the coin. Tissue Antigens 69(1), 1-9 (2007).
82. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103(12), 4619-4621 (2004).
83. Polchert D, Sobinsky J, Douglas G et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur. J. Immunol. 38(6), 1745-1755 (2008).
84. Schena F, Gambini C, Gregorio A et al. Interferon-gamma-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum. 62(9), 2776-2786 (2010).
85. Schurgers E, Kelchtermans H, Mitera T, Geboes L, Matthys P. Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T cell proliferation and collagen-induced arthritis. Arthritis Res. Ther. 12(1), R31 (2010).
86. Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 25(10), 2648-2659 (2007).
87. Nemeth K, Leelahavanichkul A, Yuen PS et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 15(1), 42-49 (2009).
88. Muller I, Vaegler M, Holzwarth C et al. Secretion of angiogenic proteins by human multipotent mesenchymal stromal cells and their clinical potential in the treatment of avascular osteonecrosis. Leukemia 22(11), 2054-2061 (2008).
89. Maggini J, Mirkin G, Bognanni I et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS ONE 5(2), e9252 (2010).
90. Napoli I, Neumann H. Protective effects of microglia in multiple sclerosis. Exp. Neurol. 225(1), 24-28 (2010).
91. Keimpema E, Fokkens MR, Nagy Z et al. Early transient presence of implanted bone marrow stem cells reduces lesion size after cerebral ischaemia in adult rats. Neuropathol. Appl. Neurobiol. 35(1), 89-102 (2009).
92. Lee JK, Jin HK, Bae JS. Bone marrow-derived mesenchymal stem cells reduce brain amyloid-beta deposition and accelerate the activation of microglia in an acutely induced Alzheimer's disease mouse model. Neurosci. Lett. 450(2), 136-141 (2009).
93. Iacobaeus E, Amoudruz P, Strom M et al The expression of VEGF A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis. PLoS ONE 6(5), e19138 (2011).
94. Mahad D, Planchon SM, Cohen JA. Mesenchymal stem cell transplantation to treat multiple sclerosis. In: Multiple Sclerosis Therapeutics (4th Edition). Cohen JA, Rudick RA (Eds). Cambridge University Press, Cambridge, UK, 520-534 (2011).
95. Connick P, Kolappan M, Crawley C et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label Phase 2a proof-of-concept study. Lancet Neurol. 11(2), 150-156 (2012).
96. Krampera M, Glennie S, Dyson J et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101(9), 3722-3729 (2003).
97. Beyth S, Borovsky Z, Mevorach D et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T cell unresponsiveness. Blood 105(5), 2214-2219 (2005).
98. Klyushnenkova E, Mosca JD, Zernetkina V et al. T cell responses to allogeneic human mesenchymal stem cells: Immunogenicity, tolerance, and suppression. J. Biomed. Sci. 12(1), 47-57 (2005).
99. Rasmusson I, Uhlin M, Le Blanc K, Levitsky V. Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J. Leukoc. Biol. 82(4), 887-893 (2007).
100. Djouad F, Pience P, Bony C et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102, 3837-3844 (2003).
101. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A Phase II study. Lancet 371, 1579-1586 (2008).
102. Kebriaei P, Isola L, Bahceci E et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol. Blood Marrow Transplant. 15(7), 804-811 (2009).
103. Hare JM, Traverse JH, Henry TD et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J. Am. Coll. Cardiol. 54(24), 2277-2286 (2009).
104. Liang J, Zhang H, Hua B et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: A pilot clinical study. Ann. Rheum. Dis. 69(8), 1423-1429 (2010).
105. Horwitz EM, Prockop DJ, FitzpatrickLla et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat. Med. 5(3), 309-313 (1999).
106. Horwitz EM, Prockop DJ, Gordon PL et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 97(5), 1227-1231 (2001).
107. Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W. Mesenchymal stem cells. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant. 30, 215-222 (2002).
108. Cahill RA, Jones OY, Klemperer M et al. Replacement of recipient stromal/mesenchymal cells after bone marrow transplantation using bone fragments and cultured osteoblast-like cells. Biol. Blood Marrow Transplant. 10(10), 709-717 (2004).
109. Ho AD, Wagner W, Franke W. Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy 10, 320-330 (2008).
110. Agashi K, Chau DYS, Shakesheff KM. The effect of delivery via narrow-bore needles on mesenchymal cells. Regen. Med. 4, 49-64 (2009).
111. Bacigalupo A, Valle M, Podesta M et al. T cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp. Hematol. 33, 819-827 (2005).
112. Murphy JM, Dixon K, Beck S, Fabian D, Feldman A, Barry F. Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. Arthritis Rheum. 46, 704-713 (2002).
113. Del Papa N, Quirici N, Soligo D et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum. 54, 2605-2615 (2006).
114. Kastrinaki MC, Sidiropoulos P, Roche S et al. Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann. Rheum. Dis. 67, 741-749 (2008).
115. Bocelli-Tyndall C, Bracci L, Spagnoli G et al. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous-And allogeneic-stimulated lymphocytes in vitro. Rheumatology 46, 403-408 (2007).
116. Larghero J, Farge D, Braccini A et al. Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Ann. Rheum. Dis. 67, 443-449 (2008).
117. Papadaki HA, Tsagournisakis M, Mastorodemos V et al. Normal bone marrow hematopoietic stem cell reserves and normal stromal cell function support the use of autologous stem cell transplantation in patients with multiple sclerosis. Bone Marrow Transplant. 36, 1053-1063 (2005).
118. Mallam E, Kemp K, Wilkins A, Rice C, Scolding N. Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. Mult. Scler. 16, 909-918 (2010).
119. Mazzanti B, Aldinucci A, Biagioli T et al. Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implications for assessment of disease activity and treatment. J. Neuroimmunol. 199, 142-150 (2008).
120. Chen-Plotkin AS, Vossel KA, Samuels MA, Chen MH. Encephalopathy, stroke and myocardial infarction with DMSO use in stem cell transplantation. Neurology 68, 859-861 (2007).
121. Sundin M, Ringden O, Sundberg B, Nava S, Gotherstrom C, Le Blanc K. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologia 92, 1208-1215 (2007).
122. Horwitz EM, Gordon PL, Koo WKK et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc. Natl Acad. Sci. USA 99, 8932-8937 (2002).
123. Brooke G, Cook M, Blair C et al. Therapeutic applications of mesenchymal stromal cells. Semin. Cell Dev. Biol. 18, 846-858 (2007).
124. Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J. Intern. Med. 262(5), 509-525 (2007).
125. Sundin M, Orvell C, Rasmusson I, Sundberg B, Ringden O, Le Blanc K. Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. Bone Marrow Transplant. 37, 1051-1059 (2006).
126. Karlsson H, Samarasinghe S, Ball LM et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T cell responses. Blood 112(3), 532-541 (2008).
127. Ringden O, Uzunel M, Rasmusson I et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81, 1390-1397 (2006).
128. Ning H, Yang F, Jiang M et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia 22(3), 593-599 (2008).
129. Prindull G, Zipori D. Environmental guidance of normal and tumor cell plasticity: Epithelial mesenchymal transitions as a paradigm. Blood 103, 2892-2899 (2004).
130. Serakinci N, Guldberg P, Burns JS et al. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 23, 5095-5098 (2004).
131. Greaves M. Molecular genetics, natural history and the demise of childhood leukaemia. Eur. J. Cancer 35, 1941-1953 (1999).
132. Houghton JM, Stoicov C, Nomura S et al. Gastric cancer originating from bone marrow-derived cells. Science 306, 1568-1571 (2004).
133. Tolar J, Nauta AJ, Osborn MJ et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 25(2), 371-379 (2007).
134. Bernardo ME, Zaffaroni N, Novara F et al. Human bone marrow-derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 67, 9142-9149 (2007).
135. Breitbach M, Bostani T, Roell W et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 110, 1362-1369 (2007).
136. Wang Y, Huso DL, Harrington J et al. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Cytotherapy 7, 509-519 (2005).
137. Rubio D, Garcia-Castro J, Martin MC et al. Spontaneous human adult stem cell transformation. Cancer Res. 65, 3035-3039 (2005).
138. Kim J, Kang JW, Park JH et al. Biological characterization of long-term cultured human mesenchymal stem cells. Arch. Pharm. Res. 32, 117-126 (2008).
139. Rosland GV, Svendsen A, Torsvik A et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 69, 5331-5339 (2009).
140. Kidd S, Spaeth E, Klopp A, Andreff M, Hall B, Marini FC. The (in)auspicious role of mesenchymal stromal cells in cancer: Be it friend or foe. Cytotherapy 10, 657-667 (2008).
141. Tabe Y, Konopleva M, Munsell MF et al. PML-RARa is associated with leptin-receptor induction: The role of mesenchymal stem cell-derived adipocytes in APL survival. Blood 103, 1815-1822 (2004).
142. Karnoub AE, Dash AB, Vo AP et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557-565 (2007).
143. Le Blanc K, Samuelsson H, Gustafsson B et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21(8), 1733-1738 (2007).
144. Coles AJ, Fox E, Vladic A et al. Alemtuzumab more effective than interferon b-1a at 5 year follow-up of CAMMS223 clinical trial. Neurology 78(14), 1069-1078 (2012).
145. Liu ZJ, Zhuge Y, Velazquez OC. Trafficking and differentiation of mesenchymal stem cells. J. Cell. Biochem. 106(6), 984-991 (2009).
146. Ruster B, Gottig S, Ludwig RJ et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 108(12), 3938-3944 (2006).
147. Sackstein R, Merzaban JS, Cain DW et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat. Med. 14(2), 181-187 (2008).
148. Barkhof F, Rocca M, Francis G et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon b1a. Ann. Neurol. 53, 718-724 (2003).
149. Tintore M, Rovira M, Rio J et al. New diagnostic criteria for multiple sclerosis. Application in first demyelinating episode. Neurology 60, 27-30 (2003).
150. Caimi PF, Reese J, Lee Z, Lazarus HM. Emerging therapeutic approaches for multipotent mesenchymal stromal cells. Curr. Opin Hematol. 17(6), 505-513 (2010).
151. Mendez-Ferrer S, Michurina TV, Ferraro F et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466(7308), 829-834 (2010).
152. Lazarus HM, Koc ON, Devine SM et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol. Blood Marrow Transplant. 11(5), 389-398 (2005).
153. Koc ON, Gerson SL, Cooper BW et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J. Clin. Oncol. 18(2), 307-316 (2000).
154. Prinz M, Garbe F, Schmidt H et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J. Clin. Invest. 116(2), 456-464 (2006).
155. Marta M, Andersson A, Isaksson M, Kampe O, Lobell A. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur. J. Immunol. 38(2), 565-575 (2008).
156. Bsibsi M, Ravid R, Gveric D, Van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J. Neuropathol. Exp. Neurol. 61(11), 1013-1021 (2002).
157. Reynolds JM, Pappu BP, Peng J et al. Toll-like receptor 2 signaling in CD4(+) T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease. Immunity 32(5), 692-702 (2010).
158. Waldner H, Collins M, Kuchroo VK. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J. Clin. Invest. 113(7), 990-997 (2004).
159. Hwa Cho H, Bae YC, Jung JS. Role of Toll-like receptors on human adipose-derived stromal cells. Stem Cells 24(12), 2744-2752 (2006).
160. Lombardo E, DelaRosa O, Mancheno-Corvo P, Menta R, Ramirez C, Buscher D. Toll-like receptor-mediated signaling in human adipose-derived stem cells: Implications for immunogenicity and immunosuppressive potential. Tissue Eng. Part A 15(7), 1579-1589 (2009).
161. Liotta F, Angeli R, Cosmi L et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T cell modulatory activity by impairing notch signaling. Stem Cells 26(1), 279-289 (2008).
162. Kerfoot SM, Long EM, Hickey MJ et al. TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J. Immunol. 173(11), 7070-7077 (2004).
163. Ichikawa HT, Williams LP, Segal BM. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J. Immunol. 169(5), 2781-2787 (2002).
164. Tigno-Aranjuez JT, Jaini R, Tuohy VK, Lehmann PV, Tary-Lehmann M. Encephalitogenicity of complete Freund's adjuvant relative to CpG is linked to induction of Th17 cells. J. Immunol. 183(9), 5654-5661 (2009).
165. Moyeddin Bonab M, Yazdanbakhsh S, Loft J et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Iran. J. Immunol. 4, 50-57 (2007).
166. Liang J, Zhang H, Hua B et al. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult. Scler. 15, 644-646 (2009).
167. Riordan NH, Ichim TE, Min W-P et al. Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J. Transl Med. 7, 29 (2009).
168. Karussis D, Karageorgiou C, Vaknin-Dembinsky A et al. Safety and immunologic effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch. Neurol. 67, 1187-1194 (2010).
169. Yamout B, Hourani R, Salti H et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study. J. Neuroimmunol. 227, 185-189 (2010).
170. Rice CM, Whone AL, Marks DI, Butler S, Brooks DJ, Scolding NJ. A safety and feasibility study of intravenous autologous bone marrow stem cells in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 78, 1036 (2007).
171. Scolding N, Marks D, Rice C. Autologous mesenchymal bone marrow stem cells: Practical considerations. J. Neurol. Sci. 265, 111-115 (2008).